Hondalus M K, Bardarov S, Russell R, Chan J, Jacobs W R, Bloom B R
Howard Hughes Medical Research Institute, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Infect Immun. 2000 May;68(5):2888-98. doi: 10.1128/IAI.68.5.2888-2898.2000.
Attenuated mutants of Mycobacterium tuberculosis represent potential vaccine candidates for the prevention of tuberculosis. It is known that auxotrophs of a variety of bacteria are attenuated in vivo and yet provide protection against challenge with wild-type organisms. A leucine auxotroph of M. tuberculosis was created by allelic exchange, replacing wild-type leuD (Rv2987c), encoding isopropyl malate isomerase, with a mutant copy of the gene in which 359 bp had been deleted, creating a strain requiring exogenous leucine supplementation for growth in vitro. The frequency of reversion to prototrophy was <10(-11). In contrast to wild-type M. tuberculosis, the DeltaleuD mutant was unable to replicate in macrophages in vitro. Its attenuation in vivo and safety as a vaccine were established by the fact that it caused no deaths in immunodeficient SCID mice. Complementation of the mutant with wild-type leuD abolished the requirement for leucine supplementation and restored the ability of the strain to grow both in macrophages and in SCID mice, thus confirming that the attenuated phenotype was due to the DeltaleuD mutation. As a test of the vaccine potential of the leucine auxotroph, immunocompetent BALB/c mice, susceptible to fatal infection with wild-type M. tuberculosis, were immunized with the DeltaleuD mutant and subsequently challenged with virulent M. tuberculosis by both the intravenous and aerosol routes. A comparison group of mice was immunized with conventional Mycobacterium bovis BCG vaccine. Whereas all unvaccinated mice succumbed to intravenous infection within 15 weeks, mice immunized with either BCG or the DeltaleuD mutant of M. tuberculosis exhibited enhanced and statistically equivalent survival curves. However, the leuD auxotroph was less effective than live BCG in reducing organ burdens and tissue pathology of mice challenged by either route. We conclude that attenuation and protection against M. tuberculosis challenge can be achieved with a leucine auxotroph and suggest that to induce optimal protection, attenuated strains of M. tuberculosis should persist long enough and be sufficiently metabolically active to synthesize relevant antigens for an extended period of time.
结核分枝杆菌减毒突变体是预防结核病的潜在疫苗候选物。已知多种细菌的营养缺陷型在体内会减毒,但仍能提供针对野生型病原体攻击的保护作用。通过等位基因交换构建了结核分枝杆菌的亮氨酸营养缺陷型,用缺失359 bp的该基因的突变拷贝取代编码异丙基苹果酸异构酶的野生型leuD(Rv2987c),从而产生了一种在体外生长需要外源亮氨酸补充的菌株。回复到原养型的频率<10^(-11)。与野生型结核分枝杆菌相比,ΔleuD突变体在体外巨噬细胞中无法复制。它在体内的减毒作用和作为疫苗的安全性通过以下事实得以证实:它在免疫缺陷的SCID小鼠中未导致死亡。用野生型leuD对突变体进行互补消除了对亮氨酸补充的需求,并恢复了该菌株在巨噬细胞和SCID小鼠中生长的能力,从而证实减毒表型是由于ΔleuD突变所致。作为对亮氨酸营养缺陷型疫苗潜力的测试,对易受野生型结核分枝杆菌致命感染的免疫活性BALB/c小鼠用ΔleuD突变体进行免疫,随后通过静脉内和气溶胶途径用强毒结核分枝杆菌进行攻击。一组对照小鼠用传统的牛分枝杆菌卡介苗疫苗进行免疫。所有未接种疫苗的小鼠在15周内死于静脉内感染,而用卡介苗或结核分枝杆菌的ΔleuD突变体免疫的小鼠表现出增强的且在统计学上等效的生存曲线。然而,亮氨酸营养缺陷型在减轻通过任何一种途径攻击的小鼠的器官负担和组织病理学方面不如活卡介苗有效。我们得出结论,亮氨酸营养缺陷型可实现对结核分枝杆菌攻击的减毒和保护作用,并表明为诱导最佳保护,结核分枝杆菌减毒株应持续足够长的时间并具有足够的代谢活性,以便在较长时间内合成相关抗原。